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Abstract. Several abnormalities have been demonstrated 
in the intestines of patients with irritable bowel syndrome 
(IBS); however, the endocrine cells in the stomachs of these 
patients have not been investigated. The aim of the present 
study was to determine whether there are any abnormali-
ties in the endocrine cells of the stomachs of patients with 
IBS using chromogranin A (CgA) as a common marker for 
endocrine cells. A total of 76 patients were included, of which 
26 presented with diarrhoea as the predominant symptom 
(IBS-D), 21 exhibited diarrhoea and constipation (IBS-M), 
and 29 experienced constipation as the predominant symptom 
(IBS-C). In addition, 59 healthy volunteers were recruited as 
controls. The patients and the controls underwent gastroscopy, 
and biopsy samples were obtained from the antrum and corpus 
of the stomach. The biopsy samples were immunostained and 
the CgA-positive cell density and the intensity of the CgA 
immunoreactivity were determined. The CgA-positive cell 
densities in the antra of patients with IBS‑M were significantly 
reduced relative to the controls (P<0.01), while the densities 
were significantly increased in the antra and corpora of the 
IBS-C patients (P<0.01 and P<0.001 respectively). The inten-
sities of CgA immunoreactivity did not differ significantly 
between the IBS patients and the controls. The abnormalities 
in the densities of endocrine cells were not associated with 
concomitant changes in the intensities of immunoreactivity; 
this may indicate unchanged synthesis and/or release of the 
hormones. In conclusion, the difference in the density of endo-
crine cells among the IBS subtypes may reflect a role of these 
cells in the differential symptomologies of these subtypes.
Introduction
Irritable bowel syndrome (IBS) is a common chronic gastroin-
testinal disorder with a prevalence of 5-20% and an incidence 
of ~200 per 100,000 individuals (1). There are currently no 
radiological, biochemical or endoscopic markers for the 
diagnosis of IBS (2), which is therefore mainly diagnosed 
by assessing the clinical symptoms of (3,4): Abdominal 
discomfort/pain, altered bowel habits and bloating/abdominal 
distension (5,6).
While IBS does not develop into serious diseases (for 
example, colon cancer) and is not associated with increased 
mortality rates (7,8), it considerably reduces quality of life, 
and is an economic burden to the patient and society due to 
direct and indirect costs (1). The direct costs are attributable 
to the evaluation and treatment of the condition, and the indi-
rect costs may be due to absenteeism from school or work, or 
presenteeism resulting in reduced productivity while at school 
or work (1).
Chromogranin A (CgA) was first isolated from secre-
tory granules from the bovine adrenal medulla (9,10). CgA 
is co-stored and co-released with monoamines and peptide 
hormones from various sites, including the endocrine cells of 
the gastrointestinal tract (9,10). CgA is commonly used as a 
marker for gut endocrine cells and endocrine tumours (9-11).
Changes in the population of CgA-immunoreactive endo-
crine cells, as a marker for the entire population of the endocrine 
cells, have been investigated in the duodenum, ileum, colon 
and rectum of IBS patients (12-14). Whereas the density of 
CgA-immunoreactive cells is reduced in the duodenum, ileum 
and colon, it does not differ from that of healthy subjects in 
the rectum. To the best of our knowledge, alterations in the 
population of CgA-immunoreactive cells in the stomach of 
patients with IBS have not been investigated. Therefore, the 
present study was undertaken to identify any changes in the 
total population of endocrine cells in the stomach, as identified 
by CgA immunoreactivity.
Materials and methods
Patients and controls. A total of 76 patients who fulfilled 
Rome III Criteria (3,4) for IBS were included in the study. 
These patients comprised 62 females and 14 males with a 
mean age of 32 years (range, 18-55 years). The predominant 
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IBS symptoms were diarrhoea (IBS-D), present in 26 patients, 
diarrhoea and constipation (IBS-M) in 21 patients, and consti-
pation (IBS-C) in 29 patients. All patients had suffered from 
IBS symptoms for a number of years and none were able to 
associate the onset of these symptoms with any particular 
event, such as a gastrointestinal infection. All patients under-
went a complete physical examination and were submitted to 
blood analysis of the following parameters: Full blood count, 
electrolytes, inflammatory markers, and liver and thyroid 
function.
Healthy volunteers without any gastrointestinal complaints 
were recruited as controls via a local announcement at Stord 
Hospital (Stord, Norway), Haukelands University Hospital 
(Bergen, Norway) and the University of Bergen (Bergen, 
Norway), as well as in local newspapers. A total of 59 healthy 
subjects were included: 15 were from the population of Stord 
city, and 44 were students or hospital employees. The controls 
comprised 43 females and 16 males with a mean age of 
38 years (range, 20-67 years).
The study was performed in accordance with the 
Declaration of Helsinki and was approved by the Committee 
for Medical Research Ethics at the University of Bergen 
(Bergen, Norway). All subjects gave oral and written consent 
to participate in the study.
Gastroscopy, histopathology and immunohistochemistry. 
Following an overnight fast, the patients and controls under-
went standard gastroscopy, during which three biopsy samples 
were obtained from the antrum and three from the corpus 
(major curvature) of the stomach. Two additional biopsy 
samples were removed from the antrum and used for a rapid 
urease test to identify the presence of Helicobacter pylori.
The biopsy samples were fixed overnight in 4% buffered 
paraformaldehyde, embedded in paraffin and cut into 5‑µm 
sections. The sections were stained with haematoxylin and 
eosin and immunostained using the avidin-biotin complex 
(ABC) method with the Vectastain ABC kit (Vector 
Laboratories, Burlingame, CA, USA). The primary antibody 
used was a monoclonal mouse antibody raised against the 
N‑terminal of purified CgA (M869; Dako, Carpinteria, CA, 
USA). The sections were incubated with primary antibody 
diluted to 1:1,000 at room temperature for 2 h. The sections 
were then washed in phosphate-buffered saline (PBS; 
pH 7.4) and incubated with biotinylated swine anti-mouse 
IgG (DakoCytomation, Glostrup, Denmark) diluted to 1:200 
for 30 min at room temperature. Subsequent to washing the 
slides in PBS buffer, the sections were incubated for 30 min 
with avidin-biotin-peroxidase complex (DakoCytomation) 
diluted to 1:100 and then immersed in 3,3'-diaminobenzidine 
peroxidase substrate (Vector Laboratories), followed by coun-
terstaining with haematoxylin.
Computerised image analysis. The number of immunoreac-
tive cells and the area of epithelial cells were measured using 
Olympus cellSens imaging software (version 1.7; Olympus, 
Tokyo, Japan) on a computer linked to an Olympus micro-
scope (type BX 43) with built-in Koehler illumination for 
transmitted light, a light-intensity manager, a switchable 
high-colour-reproductivity LED light source, a 6 V/30 W 
halogen bulb and an Olympus camera (DP 26). The number of 
CgA‑immunoreactive cells in each field was counted manually 
and the area of epithelium containing these cells was drawn 
manually using a computer. The intensity of CgA immuno-
reactivity in each field was measured using an automatic 
threshold setting. A x40 objective was used, which resulted in 
each frame (field) on the monitor representing a tissue area of 
0.035 mm2. For each subject, measurements were performed 
in ten randomly selected fields. Immunostained sections from 
the IBS patients and controls were coded and mixed, and 
measurements were conducted by the same individual who 
was blinded to the identity of the sections. The data from the 
fields were tabulated, and the cell density of the epithelium (in 
cells/mm2) and the immunoreactivity intensity were computed 
and analysed statistically.
Statistical analysis. The differences in gender and the occur-
rence of H. pylori infection between patients and controls 
were examined using Fisher's exact test, and the age differ-
ence was analysed by the Mann-Whitney nonparametric test. 
The differences among controls, all IBS patients (IBS-total), 
IBS-D, IBS-M and IBS-C patients were investigated using 
the Kruskal-Wallis nonparametric test with Dunn's post test. 
The data are presented as the mean ± the standard error of 
the mean and P<0.05 was considered to indicate a statistically 
significant difference.
Results
Patients and controls. The gender and age distributions did 
not significantly differ between the patients and the controls 
(P=0.297 and P=0.824, respectively). H. pylori infection 
was identified in three of the patients and two of the control 
subjects (as evidenced by the urease test and by histopatho-
logical examination), and its incidence did not significantly 
differ between the two groups (P=0.64).
Gastroscopy, histopathology and immunohistochemistry. 
The oesophagus, stomach and duodenum of the patients and 
the controls were macroscopically normal. Histopathological 
examination of the stomach revealed normal histology. 
CgA-immunoreactive cells were observed in the antra 
and corpora of patients and controls, and were basket- or 
flask-shaped, occasionally with a long basal cytoplasmic 
process.
Computerised image analysis. In the antra, the densities of CgA 
cells were measured as 272.5±28.6, 372.7±43.6, 274.6±41.2, 
217.0±61.9 and 685.3±100.5 cells/mm2 in the controls and the 
IBS-total, IBS-D, IBS-M and IBS-C patients, respectively. 
The Kruskal-Wallis test demonstrated that the CgA cell 
density differed significantly between the controls and the 
IBS-total and IBS subgroups (P=0.01). The Cga cell density 
was significantly lower in the IBS‑M group and significantly 
higher in the IBS-C group relative to the controls (P=0.003 
and P<0.01, respectively; Figs. 1 and 2). The intensities of 
the anti-CgA immunoreactivity were 122.2±1.4, 126.0±0.8, 
125.7±0.9, 124.7±3.7 and 127.0±1.4, in the controls and the 
IBS-total, IBS-D, IBS-M and IBS-C patients, respectively. No 
significant differences in this parameter were detected among 
any of the groups (P=0.14; Figs. 1 and 2).
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In the corpora, the densities of CgA cells were 
254.1±24.6, 391.3±43.4, 302.4±42.6, 286.9±44.9 and 
594.7±100.1 cells/mm2 in the controls and the IBS-total, IBS-D, 
IBS-M and IBS-C patients, respectively. Multi-comparison 
with the Kruskal-Wallis test demonstrated that the CgA cell 
density differed significantly between the controls and the 
IBS-total and all IBS subgroups (P=0.004), and particularly 
between patients with IBS-C and the controls (P=0.0002; 
Figs. 3 and 4). The intensities of the CgA immunoreactivity 
were 118.3±1.6, 121.4±1.0, 120.7±1.7, 124.0±2.2 and 120.7±1.7 
in the controls and the IBS-total, IBS-D, IBS-M and IBS-C 
patients, respectively. As in the antrum, this parameter did not 
differ significantly among any of the groups (P=0.29; Figs. 3 
and 4).
Discussion
The findings of the present study revealed that the density of 
all endocrine cells in the antrum and corpus of the stomach, 
as identified by CgA immunoreactivity, is abnormal in certain 
patients with IBS. This abnormality was not present for all 
IBS subtypes, the density of CgA-immunoreactive cells was 
increased in the antra and corpora of patients with IBS-C, 
and reduced in the antra of patients with IBS-M relative to the 
Figure 1. (A) CgA cell density and (B) intensity of anti-CgA immunoreac-
tivity in the stomach antra of controls and of IBS-total, IBS-D, IBS-M and 
IBS-C patients. **P<0.01 vs. controls. CgA, chromgranin A; IBS, irritable 
bowel syndrome; IBS-D, IBS diarrhoea; IBS-M, IBS diarrhoea and constipa-
tion; IBS-C, IBS constipation.
Figure 2. Antral chromogranin A-immunoreactive cells in (A) a control 
subject, (B) a patient with IBS-M and (C) a patient with IBS-C. Staining 
was performed using the avidin-biotin complex method. IBS, irritable bowel 
syndrome; IBS-M, IBS diarrhoea and constipation; IBS-C, IBS constipation.
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controls. Whereas CgA-immunoreactive cells in the antrum 
represent the population of gastrin-, serotonin- and soma-
tostatin-secreting cells, in the corpus CgA-immunoreactive 
cells represent ghrelin-, serotonin- and somatostatin-secreting 
cells (1,15,16). Thus, although CgA cell density in the antrum 
and the corpus was unchanged in IBS-D patients, changes in 
particular endocrine cells cannot be excluded.
Computerised image analysis has been used for the past 
15 years for determining the cellular concentrations of certain 
substances in a section of tissue by measuring the intensity 
of immunoreactivity produced by the colour of the immuno-
histochemical staining (17). When this practise was initially 
implemented, measuring these parameters was tedious, with 
instability in the light source also rendering the measurements 
unreliable. Subsequent advances in computer software and 
microscopic illumination have greatly improved the measure-
ment reliability. However, the intensity of immunoreactivity 
is expressed in arbitrary units and thus is only useful for 
comparisons among groups immunostained under the same 
conditions. In the present study, no significant differences 
were detected in the intensities of CgA immunoreactivity in 
the antra and the corpora of the controls and IBS patients, 
including all IBS subtypes. This indicates that the cellular 
content of CgA was similar in the controls and all types of IBS 
patients. The cellular content of CgA reflects the synthesis and 
release of CgA, and the findings suggest that these functions 
are not affected in IBS patients.
With the exception of ghrelin in the oxyntic mucosa of the 
stomach of IBS patients (15,18), to the best of our knowledge 
the endocrine cells in the stomach of IBS patients have not 
been previously investigated. The density of ghrelin-secreting 
cells in the stomach was reported to be lower in IBS-C and 
higher in IBS-D than in healthy controls (19). Abnormalities 
in the endocrine cells in other parts of the gastrointestinal 
tract, including the duodenum, ileum, colon and rectum, 
have been reported in patients with IBS (12,13,19-30). In the 
duodenum, the cell densities of gastric inhibitory polypeptid- 
and somatostatin-secreting cells were reduced in IBS-D and 
IBS-C (21). The densities of duodenal secretin- and chole-
cystokinin (CCK)-secreting cells were reduced in IBS-D 
but unchanged in IBS-C, while the duodenal serotonin cells 
Figure 3. (A) CgA cell density and (B) intensity of anti-CgA immunoreac-
tivity in the corpora of controls and of IBS-total, IBS-D, IBS-M and IBS-D 
patients. ***P<0.001 vs. controls. CgA, chromgranin A; IBS, irritable bowel 
syndrome; IBS-D, IBS diarrhoea; IBS-M, IBS diarrhoea and constipation; 
IBS-C, IBS constipation.
Figure 4. Chromogranin A cells in the corpora of (A) a control subject and 
(B) a patient with irritable bowel syndrome-C. Staining was performed using 
the avidin-biotin complex method.
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were not affected in either IBS-D or IBS (21). Furthermore, 
in postinfectious IBS, an increased number of duodenal 
CCK cells but a reduced number of serotonin-secreting cells 
have been reported (20). Densities of colonic serotonin- and 
peptide YY (PYY)-secreting cells were reportedly low in 
IBS-D and IBS-C (22). In the rectum, the densities of PYY 
and enteroglucagon‑secreting cells were significantly lower 
and the density of somatostatin‑secreting cells was signifi-
cantly higher in IBS-D and IBS-C than in controls, whereas 
the density of serotonin-secreting cells in these patients did 
not differ from that in healthy controls (24,23). Densities of 
rectal serotonin- and PYY-secreting cells in post-infectious 
IBS were reported to be elevated (26,28,30,31,32).
In conclusion, the total numbers of endocrine cells were 
abnormal in the stomachs of patients with IBS. This abnor-
mality was not associated with a change in the intensity of the 
immunoreactivity, possibly indicating unchanged synthesis 
and/or release of the hormones. In addition, the changes in 
endocrine cells observed in the present study varied among 
the IBS subtypes, which may indicate a role of the endocrine 
cells in differential symptomologies. The findings of the 
present study add to the evidence supporting the presence of 
endocrine cell abnormalities throughout the gastrointestinal 
tract in IBS patients.
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